Novavax announces launch of global vaccine programs

The 'We Do Vaccines' and 'Know Our Vax' programs are two educational initiatives that deliver vaccine information.



Yesterday, Novoxax an American biotechnology company based in Gaithersburg announced the launch of its global unbranded 'We Do Vaccines' and 'Know Our Vax' educational programs. The programs are aimed at helping people throughout the world defend their health in the fight against COVID-19 and other deadly infectious diseases like influenza. Novovax is a company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The 'We Do Vaccines' program aims to educate people about common vaccines and how they work, as well as how vaccines are made and tested and how Novavax's approach to technology distinguishes its vaccines. The 'Know Our Vax' program educates consumers about Novavax, its global strategy, and tried-and-true technology.


"Novavax' vaccines are built on a well-understood protein-based platform used for other vaccines for decades, and we are committed to fighting the current pandemic and aiding in overall global public health," said John Trizzino, Chief Commercial Officer and Chief Business Officer of Novavax. Adding, "we're proud to do our part to ensure that all stakeholders have awareness about their vaccine options through the launch of educational programs such as these." These educational programs explain the biotech company’s commitment to vaccine development and innovation. The company's COVID-19 vaccine, NVX-CoV2373, has gained conditional approval from a number of regulatory bodies throughout the world, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide.